Week of December 7th, 2020 | Vol. 9, Issue 49
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
INDUSTRY M&A SNAPSHOT

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Montage
Strategic Advisory | Generic Pharma + CDMO | Exploring full range of transaction alternatives

Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm
Provepharm Life Solutions today announces its acquisition of Apollo Pharmaceuticals USA Inc. (Florida), a company based in the United States that specializes in the commercialization of sterile injectable products for hospital use. The business activities of Apollo Pharmaceuticals USA Inc. will be merged with those of the American subsidiary of the group, located in the US (Pennsylvania). The financial terms of the deal will not be disclosed. Bourne Partners served as the exclusive financial advisor to Apollo Pharmaceuticals USA ownership in this transaction.

“We are pleased to have helped facilitate another deal in the generic pharma space, especially during a challenging year. This is our 5th generic pharma transaction in 2020,” said Jeremy Johnson, Managing Director of Bourne Partners. “This transaction is a successful outcome for all parties involved.”

Provepharm’s strategic purchase enables it to strengthen its position in the US market, particularly through the expansion of its product range, initially by integrating Apollo’s four registered products. This deal will also allow the group to streamline its commercial activity with hospitals and successfully launch its pipeline products. Positioning Provepharm Life Solutions closer to the end user will make it possible to better adapt its products and services to customers’ expectations.

RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
10 transactions totaling $845 million
Supplies, Equipment & Services
17 transactions totaling $998 million
Healthcare IT & Managed Care
8 transactions totaling $43 million
Healthcare Facilities & Distributors
11 transactions totaling $2,748 million
Pharma & Biotech
33 transactions totaling $642 million
Supplies, Equipment & Services
15 transactions totaling $326 million
Healthcare IT & Managed Care
15 transactions totaling $117 million
Healthcare Facilities & Distributors
2 transactions
Pharma & Biotech
22 transactions totaling $3,364 million
Supplies, Equipment & Services
9 transactions totaling $961 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
1 transaction totaling $500 million
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
December 4, 2020 - Fierce Biotech
Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice. The company’s second venture capital round this year has raised $175 million to help accelerate its efforts and expand further into retail stores nationwide.

December 4, 2020 - Fierce Biotech
Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes. The Seattle-based company had looked for a $100 million IPO last month but has got off a major $242 million debut, giving it a fully diluted market value of $758 million. In the end, it got this major cash swag by offering 11.5 million shares at $21, above the original range of $19 to $20.

December 3, 2020 - Fierce Pharma
Becton Dickinson masterminded the prefillable syringe, and decades later, it's a technology key to the global COVID-19 vaccine rollout. And with pandemic demand surging, BD is planning to shell out $1.2 billion to expand that very business.

December 3, 2020 - Fierce Pharma
Biologics production has mushroomed in recent years with massive investments from big biopharma and contract manufacturing alike. Just over a month after its parent company pledged to expand clinical supply of those drugs, a North Carolina-based CDMO has even bigger plans for its commercial ops.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.